Rachna T Shroff

May 29, 2024 | onclive.com | Milind M. Javle |Rachna T Shroff |Steven West

Prospective Data Reveal Most Young Survivors of Breast Cancer Could Successfully Give BirthHPV Vaccinations Associated With Lower Rates of HPV-Caused Cancers in Patients Under 40 Years of Age

Feb 27, 2024 | healio.com | Rachna T Shroff |Cory Perla |Mindy Valcarcel

You've successfully added Hematology Oncology: Gastrointestinal Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this video, Rachna T. Shroff, MD, MS, discusses updated data on tinengotinib, presented at ASCO Gastrointestinal Cancers Symposium.

Feb 15, 2024 | healio.com | Rachna T Shroff |Cory Perla |Mindy Valcarcel

You've successfully added to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this video, Rachna T. Shroff, MD, MS, discusses data from the CIRCULATE and COBRA studies, which evaluated the role of circulating tumor DNA in guiding treatment decisions for patients with colon cancer.

Feb 5, 2024 | healio.com | Rachna T Shroff |Cory Perla |Mindy Valcarcel

You've successfully added Hematology Oncology: Gastrointestinal Cancer to your alerts. You will receive an email when new content is published. Click Here to Manage Email Alerts We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. In this video, Rachna T. Shroff, MD, MS, of University of Arizona Cancer Center, discusses highlights from ASCO Gastrointestinal Cancers Symposium.

Nov 16, 2023 | targetedonc.com | Rohit Gosain |Rahul Gosain |Rachna T Shroff

November 16, 2023Rachna Shroff, MD, chief of the Division of Hematology and Oncology in the Department of Medicine at the University of Arizona College of Medicine, highlights key data from the Codebreak300 study evaluating if the combination of sotorasib and panitumumab is superior to standard-of-care trifluridine/tipiracil or regorafenib in the setting of chemorefractory metastatic colorectal cancer. Related ContentRelated Content